Myeloproliferative neoplasms trials in France

In France 40 Also abroad 210

40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Where
Amiens Cedex 1, Angers, Brest, Le Kremlin-Bicetre, Lens, Marseille, Nancy, Nice, Nimes Cedex 9, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse Cedex 9
Age
18 years and over
People
460 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Bordeaux, Caen Cedex 9, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes Cedex 1, Nice, Paris, Poitiers, Strasbourg Cedex 2, Toulouse, Vandoeuvre Les Nancy
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 3Taking people
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Where
Brest, Lille, Marseille, Nice, Paris, Pessac, Pierre-Bénite, Poitiers, Strasbourg Cedex 2
Age
18 years and over
People
324 worldwide
Run by
Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00
Phase 3Taking people
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Where
Amiens, Bordeaux, Brest, Créteil, Le Kremlin-Bicêtre, Nice, Paris, Poitiers, Toulouse
Age
18 years and over
People
426 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00
Phase 1Taking people
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Where
Paris, Pierre-Bénite, Toulouse
Age
18 years and over
People
300 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00
Phase 2Taking people
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Where
Angers, Brest, Nice, Nimes Cedex 9, Paris, Pierre-Bénite, Poitiers
Age
18 years and over
People
68 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06517875 · EU 2024-518225-15-00
Phase 1Taking people
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Where
Bordeaux, Paris, Villejuif
Age
18 years and over
People
218 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00
No phaseTaking people
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
Where
Angers, Cholet, Saumur
Age
18 years and over
People
70
Run by
University Hospital, Angers
See details and how to joinNCT06361641
Phase 3Taking people
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Where
Angers, Brest, Clermont-Ferrand, Marseille, Nice, Nimes Cedex 9, Pierre-Bénite, Rennes Cedex 9, Saint-Priest-en-Jarez, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
250 worldwide
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00
Phase 1Taking people
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Where
Nice, Paris, Toulouse Cedex 9
Age
18 years and over
People
100 worldwide
Run by
Prelude Therapeutics Incorporated
See details and how to joinNCT07469891 · EU 2026-525484-40-00
No phaseTaking people
Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
Where
Oullins-Pierre-Bénite
Age
18 years and over
People
13
Run by
Hospices Civils de Lyon
See details and how to joinNCT06781099
Phase 1Taking people
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Where
Paris
Age
18 years and over
People
256 worldwide
Run by
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
See details and how to joinNCT06343805 · EU 2025-522033-64-00
Phase 1/2Taking people
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Where
Amiens, Angers, Nice, Nimes Cedex 9, Paris, Pierre-Bénite, Poitiers, Villejuif
Age
18 years and over
People
240 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00
Phase 2Taking people
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Where
Angers, Bordeaux, Nîmes, Paris, Pierre-Bénite, Saint-Priest-en-Jarez, Tours Cedex 9
Age
18 years and over
People
38 worldwide
Run by
Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 · EU 2024-511309-47-00
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Nice, Pessac
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Paris, Poitiers, Toulouse
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
Where
Amiens Cedex 1, Angers, Brest, Lille Cedex, Lyon, Nantes, Nice, Nîmes, Paris, Pessac, Pierre-Bénite, Poitiers, Strasbourg Cedex 2, Toulouse, Tours
Age
18 years and over
People
126 worldwide
Run by
Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 · EU 2023-504724-25-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Lille Cedex, Nice, Paris
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Angers, Créteil, La Tronche, Lille, Marseille, Paris, Pessac, Pierre-Bénite, Strasbourg, Toulouse, Tours
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 2Taking people
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
Where
Brest, Marseille, Nantes, Nice, Nîmes, Paris, Poitiers, Villejuif
Age
18 years and over
People
50 worldwide
Run by
Step Pharma, SAS
See details and how to joinNCT06786234
No phaseTaking people
Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities
Where
Amiens
Age
18 years and over
People
300
Run by
Centre Hospitalier Universitaire, Amiens
See details and how to joinNCT05714592
No phaseTaking people
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms
Where
Villejuif
Age
18 years and over
People
80
Run by
Institut National de la Santé Et de la Recherche Médicale, France
See details and how to joinNCT05850273
Phase 3Taking people
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Where
Amiens Cedex 1, Angers, Argenteuil Cedex, Nice, Paris, Saint-Quentin, Tours Cedex 9, Troyes
Age
18 years and over
People
220 worldwide
Run by
Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00
No phaseNot yet taking people in France
Clonal Hematopoiesis of Immunological Significance
Where
Paris
Age
18 years and over
People
5,000
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT05969821
Phase 3Taking people
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Where
Angers, Annecy, Argenteuil, Avignon, Bayonne, Béziers, Bordeaux, Brest, Cesson-Sévigné, Clermont-Ferrand, Créteil, Grenoble, La Roche-sur-Yon, Le Havre, Le Mans, Libourne, Limoges, Lyon, Montpellier, Morlaix, Nancy, Nantes, Orléans, Paris, Périgueux, Perpignan, Quimper, Rennes, Rochefort, Roubaix, Rouen, Saint-Denis, Saint-Pierre, Saint-Priest-en-Jarez, Strasbourg, Tours, Vannes, Versailles, Villejuif, Villeurbanne
Age
18 years and over
People
1,308
Run by
University Hospital, Brest
See details and how to joinNCT05198960